Author:
Bergamaschi Laura,Zorza Marta,Rini Francesca,Perrone Federica,Rivoltini Licia,Gronchi Alessandro,Pasquali Sandro,Zaffaroni Nadia,Vallacchi Viviana,Colombo Chiara
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Board WC of TE. Soft tissue and bone tumours [Internet]. [cited 2024 Feb 9]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Soft-Tissue-And-Bone-Tumours-2020
2. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107.
3. Colombo C, Fiore M, Grignani G, Tolomeo F, Merlini A, Palassini E, et al. A prospective observational study of active surveillance in primary desmoid fibromatosis. Clin Cancer Res. 2022;28(18):4027–32.
4. Schut ARW, Timbergen MJM, van Broekhoven DLM, van Dalen T, van Houdt WJ, Bonenkamp JJ, et al. A nationwide prospective clinical trial on active surveillance in patients with non-intraabdominal desmoid-type fibromatosis: the GRAFITI trial. Ann Surg. 2023;277(4):689–96.
5. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696–702.